Andrew Quon
Publications
- Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. Cancer. 2013; (7): 1349-56
- Metabolic tumor volume predicts disease progression and survival in patients with squamous cell carcinoma of the anal canal. J Nucl Med. 2013; (1): 27-32
- Comparison of MRI and ¹⁸F-NaF PET/CT in patients with patellofemoral pain. J Magn Reson Imaging. 2012; (4): 928-32
- Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy. J Card Fail. 2012; (10): 804-9
- Initial investigation of ¹⁸F-NaF PET/CT for identification of vertebral sites amenable to surgical revision after spinal fusion surgery. Eur J Nucl Med Mol Imaging. 2012; (11): 1737-44
- Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy. Lung Cancer. 2012; (3): 219-24
- Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer. Clin Lung Cancer. 2012; (1): 52-8
- Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data--methods and preliminary results. Radiology. 2012; (2): 387-96
- Patients with patellofemoral pain exhibit elevated bone metabolic activity at the patellofemoral joint. J Orthop Res. 2012; (2): 209-13
- Positron emission tomography for predicting pathologic response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Am J Clin Oncol. 2012; (4): 334-9
- Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer. Int J Radiat Oncol Biol Phys. 2012; (2): 471-7
- Prognostic PET 18F-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer. Cancer Res. 2012; (15): 3725-34
- 18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. Nucl Med Commun. 2011; (5): 343-7
- Pattern of 18F-FDG uptake in the spinal cord in patients with non-central nervous system malignancy. Spine (Phila Pa 1976). 2011; (21): E1395-401
- Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011; (2): 514-21
- Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer. J Thorac Oncol. 2011; (5): 920-6
- Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010; (4): 775-7; quiz 918
- Rosiglitazone increases myocardial glucose metabolism in insulin-resistant cardiomyopathy. J Am Coll Cardiol. 2010; (9): 926-7
- Simulations of virtual PET/CT 3-D bronchoscopy imaging using a physical porcine lung-heart phantom. Mol Imaging Biol. 2009 Jul-Aug; (4): 275-82
- Detection of solitary humeral metastasis from pancreatic adenocarcinoma with F-18 FDG PET/CT. Clin Nucl Med. 2009; (5): 312-3
- Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging. 2009; (12): 1952-9
- Focal fat mimicking multiple hepatic metastases on FDG PET/CT imaging. Eur J Nucl Med Mol Imaging. 2009; (9): 1527
- Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009; (5): 1335-41
- Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med. 2009; (4): 501-5
- Positron emission tomography/computed tomography: the current technology and applications. Radiol Clin North Am. 2009; (1): 147-60
- Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009; (3): 665-72
- (18)F-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan? Hell J Nucl Med. 2008 Sep-Dec; (3): 153-6
- 123I MIBG mapping with intraoperative gamma probe for recurrent neuroblastoma. Mol Imaging Biol. 2008 Jan-Feb; (1): 19-23
- 18F-FDG PET/CT evaluation of patients with ovarian carcinoma. Nucl Med Commun. 2008; (12): 1046-51
- Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2008; (3): 678-86
- Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer. Eur J Nucl Med Mol Imaging. 2008; (3): 527-31
- PET/CT imaging of gastrointestinal stromal tumor with calcified peritoneal implants after imatinib therapy. Clin Nucl Med. 2008; (12): 864-5
- 2-Deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma. Mol Imaging Biol. 2007 Jan-Feb; (1): 50-7
- Advances in metabolic imaging for surgical oncology. Surg Oncol Clin N Am. 2007; (2): 273-92
- Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. J Nucl Med. 2007: 58S-67S
- Clinical value of including the head and lower extremities in 18F-FDG PET/CT imaging for patients with malignant melanoma. Nucl Med Commun. 2007; (9): 688-95
- Detection of bone metastases: assessment of integrated FDG PET/CT imaging. Radiology. 2007; (1): 204-11
- FDG PET/CT detection of a gossypiboma in the neck. Clin Nucl Med. 2007; (11): 893-5
- Impact of integrated PET/CT on variability of target volume delineation in rectal cancer. Technol Cancer Res Treat. 2007; (1): 31-6
- Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. J Clin Oncol. 2007; (25): 3902-7
- Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007; (2): 328-33
- Molecular imaging techniques in body imaging. Radiology. 2007; (2): 333-56
- No apparent alteration of F-18 FDG biodistribution when injected shortly after insulin glargine. Clin Nucl Med. 2007; (4): 302-3
- RT_Image: an open-source tool for investigating PET in radiation oncology. Technol Cancer Res Treat. 2007; (2): 111-21
- Merkel cell carcinoma: Is there a role for 2-deoxy-2-[f-18]fluoro-D-glucose-positron emission tomography/computed tomography? Mol Imaging Biol. 2006 Jul-Aug; (4): 212-7
- "Flying through" and "flying around" a PET/CT scan: Pilot study and development of 3D integrated 18F-FDG PET/CT for virtual bronchoscopy and colonoscopy. J Nucl Med. 2006; (7): 1081-7
- Diagnosis of aseptic deep venous thrombosis of the upper extremity in a cancer patient using fluorine-18 fluorodeoxyglucose positron emission tomography/computerized tomography (FDG PET/CT). Ann Nucl Med. 2006; (2): 151-5
- F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomas. Clin Nucl Med. 2006; (12): 754-60
- F-18 fluorodeoxyglucose PET/CT as an imaging tool for staging and restaging cutaneous angiosarcoma of the scalp. Clin Nucl Med. 2006; (9): 534-7
- Sonography of the abnormal parathyroid gland. Ultrasound Q. 2006; (4): 253-62
- Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol. 2006; (5): 577-84
- Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol. 2005 Sep-Oct; (5): 369-76
- FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol. 2005; (8): 1664-73
- Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol. 2004 Nov-Dec; (6): 411-6
- Conventional imaging and 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of patients with previously treated Hodgkin's disease. Mol Imaging Biol. 2004 Jan-Feb; (1): 47-54
- Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability. J Nucl Med. 2004; (5): 797-801
- Conventional imaging and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of previously treated non-Hodgkin's lymphoma patients. Mol Imaging Biol. 2003 Jul-Aug; (4): 232-9
- Relationship between 18F-FDG uptake and breast density in women with normal breast tissue. J Nucl Med. 2003; (8): 1238-42
- Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest. 2003; (2): 608-13
Help
Trial Administration